BAY79-4980 Compared to rFVIII-FS in Previously Treated Patients With Severe Hemophilia A
Public ClinicalTrials.gov record NCT00623727. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
Randomized, Active-controlled, Double-blind, Parallel Design Study to Evaluate the Efficacy and Safety of a Once-a-week Prophylaxis Treatment With BAY79-4980 Compared to Three Times-per-week Prophylaxis With rFVIII-FS in Previously Treated Patients With Severe Hemophilia A
Study identification
- NCT ID
- NCT00623727
- Recruitment status
- Terminated
- Study type
- Interventional
- Phase
- Phase 2
- Lead sponsor
- Bayer
- Industry
- Enrollment
- 143 participants
Conditions and interventions
Conditions
Interventions
- rFVIII-FS/pegylated liposomes (BAY79-4980) Biological
- rFVIII-FS/WFI (BAY14-2222) Biological
Biological
Eligibility (public fields only)
- Age range
- 12 Years to 70 Years
- Sex
- Male
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- May 31, 2008
- Primary completion
- Mar 31, 2010
- Completion
- Sep 30, 2010
- Last update posted
- Jul 14, 2013
2008 – 2010
United States locations
- U.S. sites
- 20
- U.S. states
- 15
- U.S. cities
- 20
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Not listed | Orange | California | 92868 | — |
| Not listed | Sacramento | California | 95817 | — |
| Not listed | San Francisco | California | 94143-0324 | — |
| Not listed | Aurora | Colorado | 80045 | — |
| Not listed | New Orleans | Louisiana | 70112-2699 | — |
| Not listed | Boston | Massachusetts | 02115 | — |
| Not listed | Detroit | Michigan | 48202 | — |
| Not listed | East Lansing | Michigan | 48823 | — |
| Not listed | Rochester | Minnesota | 55905 | — |
| Not listed | Kansas City | Missouri | 64108-9898 | — |
| Not listed | Las Vegas | Nevada | 89109-2803 | — |
| Not listed | Albuquerque | New Mexico | 87131-0001 | — |
| Not listed | Buffalo | New York | 14215 | — |
| Not listed | Rochester | New York | 14621 | — |
| Not listed | Winston-Salem | North Carolina | 27157-1009 | — |
| Not listed | Cincinnati | Ohio | 45229 | — |
| Not listed | Philadelphia | Pennsylvania | 19104-0506 | — |
| Not listed | Pittsburgh | Pennsylvania | 15213 | — |
| Not listed | Houston | Texas | 77030 | — |
| Not listed | Milwaukee | Wisconsin | 53226 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 75 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00623727, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jul 14, 2013 · Synced Jul 24, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT00623727 live on ClinicalTrials.gov.